Diabetic Complications and Economic Fundamentals
CFO News Room
NOVEMBER 12, 2022
California lawmakers recently passed the CalRx Biosimilar Insulin Initiative. The legislation aims to lower the cost of insulin, a life-prolonging medication for many diabetics, by investing $100 million, half designated for developing a biosimilar insulin and half for producing it. The end goal is to make insulin more affordable and accessible for Californian diabetics.
Let's personalize your content